Brief: Biomarin Announces Positive Pivotal Data For Palynziq® (Pegvaliase-Pqpz) In Adolescents With Phenylketonuria
02/04/2025 14:14
April 2 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O: BIOMARIN ANNOUNCES POSITIVE PIVOTAL DATA FOR PALYNZIQ® (PEGVALIASE-PQPZ) IN ADOLESCENTS WITH PHENYLKETONURIA BIOMARIN PHARMACEUTICAL INC - TO SUBMIT FOR REGULATORY APPROVAL LATER THIS YEAR Source text: ID:nPn4xVSNFa Further company coverage: BMRN.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on BioMarin Pharmaceutical
See all newsUS RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Brief: Biomarin Pharmaceutical Expects Q3 2026 Pre-Tax Charges Of $283 Million For Bought Ipr&D Expense
Brief: Biomarin Appoints Cara Bauer As Chief People Officer
Brief: Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026
U.S. STOCKS ON THE MOVE-GitLab, California utilities, Herbalife